Abstract

Background and objective: In a subset of systemic sclerosis (SSc) patients (pts), anti-CENP-A Ab cross reacts with a FOXE-3-derived peptide (FOXE3p), which presents a striking homology with one (Ap17-30) of the 2 immunodominant epitopes of CENP-A. Preliminary analysis, obtained by absorbance binding, showed that active disease was less likely to occur in anti- FOXE-3+ patients as compared to anti- FOXE-3- patients. Here, we have set up a titration assay using appropriate standards to quantify IgG anti-FOXE-3 and to define whether any clinical correlate exist with the presence of anti FOXE3. As control, clinical correlates with the level of antibodies to Ap17-30 and to the 2nd immunodominant epitope of CENP-A (spanning amino acids 1-to 17, Ap1-17) were also evaluated. Methods: Ap17-30, FOXE3p and Ap1-17 were synthesized at Primm peptide synthesis service (Naples, Italy). The reactivity of serum IgG to specific peptides was measured by indirect ELISAs, using BSA-conjugated peptide as coating reagents and HRP-conjugated xeno-Ab to the Fc portion of human IgG as probe. Sera from 117 SSc pts were tested for anti-centromere and anti-topoisomerase Ab (Diamedix). Calibration curves to measure the levels of Ab were settled, using IgG from sera purified by affinity column coupled to Ap17-30 and Ap1-17 peptides. Clinical records were reviewed to achieve demographic data and information about organ involvement and disease activity, previously evaluated according to a core set of 10 variables. Control sera were obtained from SLE (#47 pts) and from healthy blood donor (HBD) (#25 pts). Results: Purify IgG anti-Ap1-17 and anti-Ap17-30 were used to set-up a standard calibration curve to measure serum levels of anti-Ap1-17 (detection limit range: 2.68-6037ug/ml) and Ap17-30 (0.36-32.85 ug/ml) respectively. As anti-Ap17-30 cross-react with FOXE-3, calibration curve to measure serum levels of Abs to this peptide was achieved using purified anti-Ap17-30 IgG and FOXE-3p as coating reagents (detection limit range: 9.25-880 ug/ml). Of 117 SSc sera, 68 (58.1%) were anti-CENP positive (CENP+) and 94% (#65) of them reacted with Ap17-30 and/or Ap1-17, while no reactivity was observed on the replacement of CENP+ with CENP-, SLE, and HBD sera. The best cut-off concentration of Ab levels able to discriminate CENP+ from CENP- patients (obtained with ROC analysis) were >10.4 ug/ml (sensitivity: 86.8, specificity 98%), >1.2ug/ml (sens. 83%, spec. 96%) and > 74.5 ug/ml (sens.>52.6%, spec. 90%) for anti-Ap1-17, anti-Ap17-30 and anti-FOXE3p respectively. Following dichotomization of CENP+ patients according to their disease activity index score in group 1 (61 patients with score <3), and group 2 (7 patients with score> 3; active disease), a Fisher exact test showed a statistical association of FOXE3p+ sera with group 1 patients (p=0.003, OR: 39.5). Conclusion: Our data confirm the identification of a subset of patients (FOXE3+) that are less likely to have active disease.

Autore Pugliese

• Favoino Elvira , Perosa Federico , Racanelli Vito

Tutti gli autori

• FAVOINO E.;PEROSA F.;RACANELLI V.

Titolo volume/Rivista

Non Disponibile

Anno di pubblicazione

2012

ISSN

0048-7449

ISBN

Non Disponibile

Numero di citazioni Wos

Nessuna citazione

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

Non Disponibile

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile